Sight Sciences Inc (SGHT) - Total Assets
Based on the latest financial reports, Sight Sciences Inc (SGHT) holds total assets worth $116.26 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Sight Sciences Inc (SGHT) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Sight Sciences Inc - Total Assets Trend (2018–2024)
This chart illustrates how Sight Sciences Inc's total assets have evolved over time, based on quarterly financial data. Check Sight Sciences Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Sight Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sight Sciences Inc's total assets of $116.26 Million consist of 97.9% current assets and 2.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.3% |
| Accounts Receivable | $10.79 Million | 7.6% |
| Inventory | $6.33 Million | 4.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Sight Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sight Sciences Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sight Sciences Inc's current assets represent 97.9% of total assets in 2024, an increase from 88.5% in 2018.
- Cash Position: Cash and equivalents constituted 84.3% of total assets in 2024, up from 52.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 7.6% of total assets.
Sight Sciences Inc Competitors by Total Assets
Key competitors of Sight Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$91.48 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
LIFETECH SCI.DL-00000125
F:81X
|
Germany | €5.01 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Shanghai Kinetic Medical Co
SHE:300326
|
China | CN¥3.38 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
Sight Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.60 | 10.18 | 7.58 |
| Quick Ratio | 8.93 | 9.74 | 7.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $101.76 Million | $126.67 Million | $61.32 Million |
Sight Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Sight Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.41 |
| Latest Market Cap to Assets Ratio | 1.94 |
| Asset Growth Rate (YoY) | -14.3% |
| Total Assets | $142.84 Million |
| Market Capitalization | $277.05 Million USD |
Valuation Analysis
Above Book Valuation: The market values Sight Sciences Inc's assets above their book value (1.94x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Sight Sciences Inc's assets decreased by 14.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sight Sciences Inc (2018–2024)
The table below shows the annual total assets of Sight Sciences Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $142.84 Million | -14.29% |
| 2023-12-31 | $166.65 Million | -21.79% |
| 2022-12-31 | $213.07 Million | -23.95% |
| 2021-12-31 | $280.19 Million | +284.84% |
| 2020-12-31 | $72.81 Million | +136.84% |
| 2019-12-31 | $30.74 Million | +279.80% |
| 2018-12-31 | $8.09 Million | -- |
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeo… Read more